tbuckley/cabot-search huggingface dataset:
PROSPECTIVE ASSOCIATION OF HEART RATE VARIABILITY AND HEART FAILURE, HEART FAILURE WITH PRESERVED EJECTION FRACTION, HEART FAILURE WITH REDUCED EJECTION FRACTION IN POSTMENOPAUSAL WOMEN
Authors: Reema Qureshi, Ahmed S. Mohamed, Mary Roberts, Lisa W. Martin, Matthew A. Allison, Michael J. LaMonte, Simin Liu, Zhan-Peng Huang, JoAnn Manson, Charles Eaton
Journal: Journal of the American College of Cardiology (2018)
Master of Minimal Access Surgery (MMAS)
Authors: Kaleem Khalilullah
Journal: BMJ (2007)

Credit: BSIP/RASTOIN/SPL



FURTHER INFORMATION 

Dr Fiona Carter, director of Cuschieri Skills Unit, Ninewells Teaching Hospital and Medical School, University of Dundee, Dundee DD1 9SY Tel 01382 645857 Fax 01382 646042

This one year masters course is designed for medical graduates with an interest in minimal access surgery. The Cuschieri Skills Centre is based at Ninewells Hospital and Medical School, Dundee, and is a national training centre with expertise in providing practical courses in laparoscopic surgery. The degree is awarded by the University of Dundee.

The course provides a period of study and academic research to …
Fewer trainees are accepted to core and specialty training this year, HEE data show
Authors: Abi Rimmer
Journal: BMJ (2017)

Fewer trainees have been accepted into the first year of core and specialty training this year, data from Health Education England (HEE) show.

Figures show that the number of trainees accepted into the first year of specialty training (ST1) and core training (CT1) in 2017 has fallen by …
Vary pay increases for different groups of doctors, suggests government
Authors: Caroline White
Journal: BMJ (2012)

The government has suggested to the doctors’ pay review body that it might want to look at pay progression for the 2013-14 pay award round and consider whether some staff might be more deserving of pay increases than others.

Last year in its Autumn statement the government announced that public sector pay awards would be capped at just 1% for the two years after the current pay …
Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
Authors: Shaocong Wu, Liwu Fu
Journal: Molecular Cancer (2018)

Multidrug resistance (MDR) triggered by ATP binding cassette (ABC) transporter such as ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no commercial available MDR modulator approved by FDA was used in clinic. Tyrosine kinase inhibitors (TKIs) have been administrated to fight against cancer for decades. Almost TKI was used alone in clinic. However, drug combinations acting synergistically to kill cancer cells have become increasingly important in cancer chemotherapy as an approach for the recurrent resistant disease. Here, we summarize the effect of TKIs on enhancing the efficacy of conventional chemotherapeutic drug in ABC transporter-mediated MDR cancer cells, which encourage to further discuss and study in clinic.
After the Earthquake
Authors: Donna Pucciani
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A prospective 52-week randomized controlled trial of patient-initiated care consultations for patients with psoriasis
Authors: L.R. Khoury, T. Møller, C. Zachariae, L. Skov
Journal: British Journal of Dermatology (2018)

Treatment and care of moderate‐to‐severe psoriasis require lifelong consultations with a dermatologist with close monitoring of systemic treatment. To investigate the effect of patient‐initiated care consultation (PICC) for patients with psoriasis in a dermatology outpatient clinic. A prospective randomized controlled trial with patients on well‐controlled systemic treatment randomized to either (i) the PICC group, where they participated in one annual consultation with a dermatologist but were able to initiate consultations when needed; or (ii) routine care, where they participated in a consultation every 12–16 weeks. The primary outcome was the Dermatology Life Quality Index (DLQI). Other outcomes were safety, patient adherence and satisfaction with healthcare assessed at baseline and after 52 weeks. The study was registered with clinical trials number NCT02382081. In total 150 patients were included, with 58·0% treated with biologics, 37·3% with methotrexate and 4·7% with acitretin. At week 52 no statistically significant mean difference between groups was detected in DLQI (0·28, 95% confidence interval −0·35 to 0·9) or Psoriasis Area and Severity Index (−0·24, 95% confidence interval −0·84 to 0·36). Patients in the PICC group requested 63% fewer consultations with a dermatologist: mean 2·5 ± 0·1 vs. 5·1 ± 0·6 (P = 0·001). Patient adherence and safety with treatment monitoring were equal between groups, but the PICC group was significantly better at attending consultations than the control group (P = 0·003). PICC offers additional clinical benefits over routine care, making patients less dependent on clinical visits. The intervention adds no harm to monitoring systemic treatment, and patients report high quality of life and satisfaction with healthcare.
Understanding Titin Variants in the Age of Next-Generation Sequencing—A Titanic Challenge
Authors: Carsten G. Bönnemann
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
PAPILLARY MUSCLE RUPTURE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS FROM NATIONAL INPATIENT SAMPLE DATABASE
Authors: Bhaskar Bhardwaj, Varun Kumar, Nileshkumar Patel, Kul Aggarwal, Arun Kumar, Sudarshan Balla, Martin Alpert
Journal: Journal of the American College of Cardiology (2018)
Authorship Credit for Large Clinical Trials—Reply
Authors: Spyros D. Mentzelopoulos, Spyros G. Zakynthinos
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Margaret McCartney: Mandatory flu vaccination won’t fix the NHS
Authors: Margaret McCartney
Journal: BMJ (2018)

Bruce Keogh, national medical director for NHS England, recently called for a “serious debate on mandatory flu vaccination.”1 And the chief medical officer for England, Sally Davies, has indicated her support for mandatory flu vaccination for NHS staff.23 This would be a mistake.

Hepatitis B vaccination, for example, is a highly evidence based programme, usually requiring only three doses for lifelong protection. Flu vaccinations must be repeated every year, meaning a need for long term cooperation. Also, the benefits to healthcare workers (and hence patients) from flu vaccination are not so clear.45 Flu vaccinations may not work …
NHS Employers selects 25 organisations to promote equality and diversity
Authors: Abi Rimmer
Journal: BMJ (2015)

NHS Employers has chosen 25 organisations to develop and promote equality in the NHS workplace in 2015-16. 

The 25 were selected from 42 that had applied to be members of a partnership scheme. NHS Employers said that membership would help these organisations “network with each other and the wider NHS, expanding on the success of previous years’ partners in influencing policy and improving performance.”

The 25 organisations will …
MSc in epidemiology at the London School of Hygiene and Tropical Medicine
Authors: Michael Holmes, Neeraj Bhala
Journal: BMJ (2011)

Epidemiology is the basic science underpinning medical research and population health through the study of determinants of disease (such as smoking and social status) and patterns of illness (cardiovascular mortality and flu outbreaks). This course aims to equip clinical and non-clinical postgraduate students with the knowledge and skills to make valuable contributions to epidemiological research and population health.

We are both clinicians undertaking academic training in the science of population health, so this is the best course to understand the underlying principles. The MSc contributed one year towards our “out of programme research,” which we took after completing medical college examinations. We are both funded by the Medical Research Council (MRC), although similar funding is available from the Wellcome Trust and the National Institute for Health Research, and the London School of Hygiene and Tropical Medicine has scholarships.

Our mentors had completed or teach …
Publisher Correction: Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection
Authors: Sarina Ravens, Christian Schultze-Florey, Solaiman Raha, Inga Sandrock, Melanie Drenker, Linda Oberdörfer, Annika Reinhardt, Inga Ravens, Maleen Beck, Robert Geffers, Constantin von Kaisenberg, Michael Heuser, Felicitas Thol, Arnold Ganser, Reinhold Förster, Christian Koenecke, Immo Prinz
Journal: Nature Immunology (2018)
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries
Authors: Gunar Günther, Frank van Leth, Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Danilovits, Martin Dedicoat, Raquel Duarte, Gina Gualano, Heinke Kunst, Wiel de Lange, Vaira Leimane, Anne-Marie McLaughlin, Cecile Magis-Escurra, Inge Muylle, Veronika Polcová, Cristina Popa, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Piret Viiklepp, Christoph Lange
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in Europe. Reported treatment success rates are around 50% or less, and cure rates are even lower.To document the management and treatment outcome in patients with MDR-TB in Europe.We performed a prospective cohort study, analyzing management and treatment outcomes stratified by incidence of patients with MDR-TB in Europe. Treatment outcomes were compared by World Health Organization and alternative simplified definitions by the Tuberculosis Network European Trialsgroup (TBNET).A total of 380 patients with MDR-TB were recruited and followed up between 2010 and 2014 in 16 European countries. Patients in high-incidence countries compared with low-incidence countries were treated more frequently with standardized regimen (83.2% vs. 9.9%), had delayed treatment initiation (median, 111 vs. 28 d), developed more additional drug resistance (23% vs. 5.8%), and had increased mortality (9.4% vs. 1.9%). Only 20.1% of patients using pyrazinamide had proven susceptibility to the drug. Applying World Health Organization outcome definitions, frequency of cure (38.7% vs. 9.7%) was higher in high-incidence countries. Simplified outcome definitions that include 1 year of follow-up after the end of treatment showed similar frequency of relapse-free cure in low- (58.3%), intermediate- (55.8%), and high-incidence (57.1%) countries, but highest frequency of failure in high-incidence countries (24.1% vs. 14.6%).Conventional standard MDR-TB treatment regimens resulted in a higher frequency of failure compared with individualized treatments. Overall, cure from MDR-TB is substantially more frequent than previously anticipated, and poorly reflected by World Health Organization outcome definitions.
Wire Placement into the Dural Venous Sinuses during Central Venous Catheter Placement
Authors: Aaron Trimble, Nathaniel Ivanick
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

A 70-year-old-woman was admitted to the ICU with septic shock and was treated with fluid resuscitation, broad-spectrum antibiotics, and initiation of vasopressors.An attempt was made to insert a central venous catheter (CVC) in the right subclavian vein.The patient was placed in the Trendelenburg position, with head turned contralaterally and neutral shoulder position.Venous access was obtained with the introducer needle, using landmarks alone without complication, and the guidewire inserted to a depth that was later determined to be approximately 35 cm.The finder needle was withdrawn, and the tract dilated without difficulty.The catheter was smoothly inserted over the guidewire without resistance to a depth of approximately 17 cm.However, significant resistance was encountered in attempting to withdraw the guidewire through the catheter, and the procedure was aborted.Multiple portable bedside radiographs were obtained (Figures 1A and1B) and showed the guidewire turning cephalad up the internal jugular vein, into the skull via the sigmoid dural sinus, traveling across the right transverse sinus into the left transverse sinus (Figure 1C).The neurosurgical service was consulted, and the wire was removed using significant manual force.After removal, a computed tomography venogram revealed no vascular complications.
The prospective assessment of the prostatic cancer mortality with PSA progression in the groups treated or not treated by salvage local brachytherapy.
Authors: Karol Edward Nietupski, Anna Kulik, Pawel Wiechno, Tomasz Demkow, Piotr Peczkowski, Małgorzata Pilichowska, Grazyna Maria Poniatowska, Wojciech Michalski, Joanna Rzymkowska, Malgorzata Sadowska, Marcin Ligaj, Jakub Kucharz, Joanna Jonska-Gmyrek, Ewa Wieczorek, Katarzyna Stencel
Journal: Journal of Clinical Oncology (2018)

85 Background: The effectiveness of diagnostics of local recurrence of prostatic adenocarcinoma after radical radiotherapy and local retreatment high definition brachytherapy and its influence on the prostatic cancer survival. Methods: 55 patients with locally advanced prostatic adenocarcinoma with rising PSA level after radical radiotherapy and exclusion of distant metastases underwent prostatic biopsy. ECOG performance status 0-1 were eligible. The histopathological confirmation was obtained in 22 cases, and 33 patients had negative biopsy. In the case of positive biopsy radical salvage brachytherapy was performed in all patients. In the case of negative biopsy definitive anti-androgen therapy was administered in patients with PSA progression. Anti – androgen therapy was performed as adjuvant and neoadjuvant treatment after brachytherapy. In the course of the long (median 108months) observation we assessed prostatic specific mortality in both groups. In addition we assessed time to PSA progression during the antiandrogen therapy Results: From Mar 2002 we observed 55 patients with rising PSA after radical radiotherapy for the prostatic adenocarcinoma. We confirmed local recurrence of prostatic adenocarcinoma in 22 cases. The median time to biopsy after radiotherapy was 41months. The median observation time after post-radiotherapy biopsy was 108 months. All of the 22 patients were treated with salvage brachytherapy. There were 8 prostatic cancer specific deaths, 1 in the group treated by brachytherapy and 7 in the non-treated group. Median prostatic cancer survival (PCSOS) was 120 months in the treated group vs 75,6 months non-treated, but this difference was not statistically significant (P value 0,49). Median time to progression PSA was 108 months in the treated group vs 48 months non-treated and was not statistically significant. Significant toxicity were not reported. Conclusions: In long time observation we revealed, including the time of antiandrogen treatment depletion therapy, that in the patients with rising PSA and local recurrence treated with high-dose brachytherapy have no worse prognosis than patients with no local progression.
Abstract 16533: Extracellular Vesicles Secreted by Human Cardiac Progenitors Are an Effective Alternative to Cell Transplantation for Chronic Heart Failure
Authors: Nisa Renault, Anaïs Kervadec, Valérie Bellamy, Nadia El Harane, Léa Thiebault, Hany Nematalla, Laetitia Pidial, Mathilde Lemitre, Nicolas Cagnard, Nicoline Smit, Veronique Meijborg, Camille Brunaud, Marc Renault, Alexandre Colas, Albert Hagège, Ruben Coronel, Mark Mercola, Jean-Sébastien Silvestre, Philippe Menasché
Journal: Circulation (2016)

Introduction:  Extracellular vesicles (EV) seem to mediate the benefits of cell therapy for ischemic heart failure (IHF) but the best cellular source of EV and their mechanism of action remain unresolved.   Methods:  EV secreted by human induced pluripotent stem cell-derived cardiac progenitors (CPg) were isolated by ultracentrifugation. Myocardial infarction was induced in nude mice (permanent LAD occlusion). Three weeks later, mice with LVEF ≤ 45% received transcutaneous echo-guided injections in the peri-infarct myocardium of CPg (1.4x10 6 , n=17), EV secreted by CPg (same batch) over 48 hr (n=19) or PBS (control, n=17). Six weeks later, hearts were blindly evaluated by echocardiography, histology and gene expression profiling. In parallel,  in vitro  bio-activity assays were developed to determine if fluorescently labelled EV were internalized in cultured rat cardiomyocytes (CM) and could affect their biology following serum deprivation. CPg and EV miRNA content was also assessed by miR arrays.   Results:  In contrast to CPg or PBS, EV significantly improved cardiac function, as evidenced by decreased LV volumes (LVESV: -11%, p In vitro,  EV were internalized by CM, induced a dose-dependent increase in CM viability and proliferation and partially restored the stress-induced impairment of CM conduction velocity in multielectrode array experiments. Among the 101 most abundant EV-miR, 12 were highly conserved across species, of which 8 targeted pathways similarly endowed with a tissue-repair potential (cell differentiation, survival, proliferation).   Conclusions:  hiPS-CPg-derived EV are effective in IHF treatment, possibly, in part, through EV-mediated miR transfer fostering endogenous cardiac repair. Their benefits in terms of scale-up and regulation could make them effective substitutes for cell transplantation.
Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All
Authors: Gil Y. Melmed, Gilaad G. Kaplan, Miles P. Sparrow, Fernando S. Velayos, Leonard Baidoo, Brian Bressler, Adam S. Cheifetz, Shane M. Devlin, Peter M. Irving, Jennifer Jones, Patricia L. Kozuch, Laura E. Raffals, Corey A. Siegel
Journal: Clinical Gastroenterology and Hepatology (2018)
Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome
Authors: Yulia Orlova, Paul Rizzoli, Elizabeth Loder
Journal: JAMA Neurology (2018)

In 2006, the US Food and Drug Administration (FDA) issued an advisory warning on the risk of serotonin syndrome with concomitant use of triptans and selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) antidepressants, but the true risk of serotonin syndrome in these patients remains unknown.To assess the risk of serotonin syndrome with concomitant use of triptans and SSRI or SNRI antidepressants.This study used electronic health record data from the Partners Research Data Registry (RPDR) to identify patients who had received an International Classification of Diseases, Ninth Revision diagnosis compatible with serotonin syndrome who had been coprescribed triptans and SSRI or SNRI antidepressants in the Greater Boston, Massachusetts, area from January 1, 2001, through December 31, 2014 (14 years). Clinical information was extracted to determine whether the case met formal diagnostic criteria and had coprescription within a calendar year. Both conservative and broad case definitions were used to better characterize the spectrum of risk. Data analysis was performed from November 23, 2016, to July 15, 2017.Incidence of serotonin syndrome.The RPDR search revealed 47 968 (±3) unique patients who were prescribed triptans during the 14-year period of the study. A total of 19 017 (±3) patients were coprescribed triptans and antidepressants during the study, with a total of 30 928 person-years of exposure. Serotonin syndrome was suspected in 17 patients. Only 2 patients were classified as having definite serotonin syndrome (incidence rate, 0.6 cases per 10 000 person-years of exposure; 95% CI, 0.0-1.5). Five patients were classified as having possible serotonin syndrome (incidence rate with these 5 cases added to the 2 definite cases, 2.3 cases per 10 000 person-years of exposure; 95% CI, 0.6-3.9). The proportion of patients with triptan prescriptions who were coprescribed an SSRI or SNRI antidepressant was relatively stable during the study, ranging from 21% to 29%.The risk of serotonin syndrome associated with concomitant use of triptans and SSRIs or SNRIs was low. Coprescription of these drugs is common and did not decrease after the 2006 FDA advisory. Our results cast doubt on the validity of the FDA advisory and suggest that it should be reconsidered.